William Anderson

List of Publications by Year in Descending Order

105 papers	2,881 citations	32 h-index	50 g-index
111 ext. papers	3,532 ext. citations	6.9 avg, IF	4.82 L-index

#	Paper	IF	Citations
105	ATRT-20. Novel prognostic molecular signatures for improved risk-classification of Atypical Teratoid Rhabdoid Tumours. *Neuro-Oncology*, **2022**, 24, i7-i7	1	
104	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.. *European Journal of Cancer*, **2021**,	7.5	3
103	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. *Pediatric Nephrology*, **2021**, 1	3.2	1
102	Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. *Cancers*, **2021**, 13,	6.6	3
101	Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. *Critical Reviews in Oncology/Hematology*, **2021**, 161, 103325	7	10
100	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. *Blood*, **2021**, 137, 2992-2997	2.2	5
99	Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. *Children*, **2021**, 8,	2.8	3
98	Fluorescence imaging in pediatric surgery: State-of-the-art and future perspectives. *Journal of Pediatric Surgery*, **2021**, 56, 655-662	2.6	5
97	Importance of Magnetic Resonance Imaging With Diffusion-weighted Imaging in Guiding Biopsy of Nodular Ganglioneuroblastoma: A Case Report. *Journal of Pediatric Hematology/Oncology*, **2021**, 43, e130-e135	1.2	0
96	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. *Science Advances*, **2021**, 7,	14.3	23
95	Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. *Cell Death and Disease*, **2021**, 12, 785	9.8	4
94	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma.. *F1000Research*, **2021**, 10, 947	3.6	
93	Lineage-Independent Tumors in Bilateral Neuroblastoma. *New England Journal of Medicine*, **2020**, 383, 1860-1865	59.2	9
92	Noninvasive MRI Native T Mapping Detects Response to -targeted Therapies in the Th- Model of Neuroblastoma. *Cancer Research*, **2020**, 80, 3424-3435	10.1	9
91	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. *European Journal of Cancer*, **2020**, 127, 52-66	7.5	26
90	Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. *Science Translational Medicine*, **2020**, 12,	17.5	37
89	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. *Nature Communications*, **2020**, 11, 4324	17.4	32

88	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. *Cancers*, **2020**, 12,	6.6	3
87	Engineering cells limits tonic signaling associated with chimeric antigen receptors. *Science Signaling*, **2019**, 12,	8.8	10
86	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. *European Journal of Cancer*, **2019**, 121, 224-235	7.5	21
85	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. *Cancer Research*, **2019**, 79, 2978-2991	10.1	8
84	Identification of new Wilms tumour predisposition genes: an exome sequencing study. *The Lancet Child and Adolescent Health*, **2019**, 3, 322-331	14.5	46
83	Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. *PLoS ONE*, **2019**, 14, e0216373	3.7	9
82	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. *Oncology Reports*, **2019**, 42, 35-42	3.5	9
81	Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples. *F1000Research*, **2019**, 8, 823	3.6	8
80	Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. *Cancer Research*, **2019**, 79, 5382-5393	10.1	21
79	Embryonal precursors of Wilms tumor. *Science*, **2019**, 366, 1247-1251	33.3	40
78	The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. *Human Pathology*, **2019**, 86, 182-192	3.7	4
77	Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. *Molecular Therapy*, **2018**, 26, 354-365	11.7	102
76	Antibody based therapy for childhood solid cancers. *Current Opinion in Chemical Engineering*, **2018**, 19, 153-162	5.4	0
75	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. *Frontiers in Immunology*, **2018**, 9, 1409	8.4	42
74	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. *Nature Communications*, **2018**, 9, 2378	17.4	50
73	Adoptive T Cell Therapies for Children Cancers **2018**, 161-174		
72	Developing immunotherapies for childhood cancer. *Archives of Disease in Childhood: Education and Practice Edition*, **2017**, 102, 162-165	0.5	1
71	Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. *Molecular Therapy*, **2017**, 25, 1234-1247	11.7	48

70	Unleashing the immune response against childhood solid cancers. *Pediatric Blood and Cancer*, **2017**, 64, e26548	3	5
69	Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with V9V2+ T cells. *OncoImmunology*, **2016**, 5, e1025194	7.2	18
68	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. *PLoS ONE*, **2016**, 11, e0152196	3.7	36
67	Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. *British Journal of Haematology*, **2016**, 174, 942-51	4.5	22
66	A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. *Clinical Cancer Research*, **2016**, 22, 3398-409	12.9	6
65	Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy. *OncoImmunology* , **2015**, 4, e973808	7.2	9
64	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. *Cancer Research*, **2015**, 75, 3043-53	10.1	54
63	Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. *Human Gene Therapy*, **2015**, 26, 276-85	4.8	11
62	Neuroblastoma killing properties of V2 and V2-negative T cells following expansion by artificial antigen-presenting cells. *Clinical Cancer Research*, **2014**, 20, 5720-32	12.9	59
61	Regeneration of stalled immune responses to transformed and infected cells using T cells. *Drug Discovery Today*, **2014**, 19, 787-793	8.8	3
60	A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing. *PLoS ONE*, **2014**, 9, e96531	3.7	22
59	T cells for cancer immunotherapy: A systematic review of clinical trials. *OncoImmunology*, **2014**, 3, e27572	7.2	124
58	Distant metastatic spread of molecularly proven infantile fibrosarcoma of the chest in a 2-month-old girl: case report and review of literature. *Journal of Pediatric Hematology/Oncology*, **2014**, 36, 231-3	1.2	8
57	Tumor-Associated Antigen Presentation by T-Cells in Cancer Immunotherapy. *Blood*, **2014**, 124, 1411-14	11.1	1
56	New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. *Clinical Cancer Research* , **2013**, 19, 5814-21	12.9	98
55	Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. *Clinical Cancer Research*, **2013**, 19, 1116-25	12.9	58
54	Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. *Journal of Pediatric Hematology/Oncology*, **2013**, 35, e1-3	1.2	18
53	Catechins and antitumor immunity: Not MDSC's cup of tea. *OncoImmunology*, **2013**, 2, e24443	7.2	6

52	The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases. *Fetal and Pediatric Pathology*, **2013**, 32, 298-307	1.7	13
51	Congenital malignant rhabdoid tumor of the scalp. *Journal of Cranio-Maxillo-Facial Surgery*, **2012**, 40, e258-60	3.6	7
50	Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood □T-lymphocytes. *Journal of Immunotoxicology*, **2012**, 9, 259-66	3.1	5
49	Characterisation and validation of insertions and deletions in 173 patient exomes. *PLoS ONE*, **2012**, 7, e51292	3.7	8
48	Inflammation: what role in pediatric cancer?. *Pediatric Blood and Cancer*, **2012**, 58, 659-64	3	6
47	Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. *Clinical and Translational Oncology*, **2012**, 14, 271-9	3.6	47
46	STAT3 Regulates Proliferation and Immunogenicity of the Ewing Family of Tumors In Vitro. *Sarcoma* , **2012**, 2012, 987239	3.1	9
45	Human □T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. *Journal of Immunology*, **2012**, 188, 1708-16	5.3	95
44	Licensing of □□ cells for professional antigen presentation: A new role for antibodies in regulation of antitumor immune responses. *OncoImmunology*, **2012**, 1, 1652-1654	7.2	11
43	Pilot study of F(18)-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilms' tumour: correlation with conventional imaging, pathology and immunohistochemistry. *European Journal of Cancer*, **2011**, 47, 389-96	7.5	33
42	Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors. *Journal of Pediatric Surgery*, **2011**, 46, 1197-200	2.6	4
41	Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1243-55	7.4	21
40	Patterns of shift in ADC distributions in abdominal tumours during chemotherapy-feasibility study. *Pediatric Radiology*, **2011**, 41, 99-106	2.8	37
39	Malignant rhabdoid tumors: a familial condition?. *Pediatric Blood and Cancer*, **2011**, 56, 1-2	3	3
38	PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies. *American Journal of Clinical Pathology*, **2010**, 133, 407-15	1.9	21
37	Soft Tissue Sarcoma **2010**, 216-233		2
36	The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. *Leukemia Research*, **2010**, 34, 109-15	2.7	4
35	A novel small-molecule inhibitor of IL-6 signalling. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7029-32	2.9	12

34	Clinical and pathological features of paediatric malignant rhabdoid tumours. *Pediatric Blood and Cancer*, **2010**, 54, 29-34	3	53
33	Migratory and antigen presentation functions of IFN-producing killer dendritic cells. *Cancer Research*, **2009**, 69, 6598-606	10.1	14
32	Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. *Journal of the National Cancer Institute*, **2009**, 101, 663-77	9.7	71
31	Ultrasound-guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. *Pediatric Blood and Cancer*, **2009**, 53, 356-60	3	16
30	PAX5 expression in rhabdomyosarcoma. *American Journal of Surgical Pathology*, **2009**, 33, 1575-7	6.7	9
29	Bone marrow-derived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. *Journal of Immunology*, **2008**, 181, 6654-63	5.3	19
28	Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. *Cancer Research*, **2008**, 68, 8058-65	10.1	15
27	MYCN as a target for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2008**, 57, 693-700	7.4	18
26	Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature. *Pathology and Oncology Research*, **2008**, 14, 233-8	2.6	25
25	Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X. *Pediatric Blood and Cancer*, **2008**, 50, 874-6	3	9
24	Immunohistochemical nuclear positivity for WT1 in childhood acute myeloid leukemia. *Fetal and Pediatric Pathology*, **2007**, 26, 193-7	1.7	5
23	Development of anti-PAX3 immune responses; a target for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1381-95	7.4	10
22	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival. *Blood Cells, Molecules, and Diseases*, **2007**, 39, 263-71	2.1	8
21	MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. *Expert Review of Anticancer Therapy*, **2006**, 6, 217-24	3.5	14
20	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. *Growth Factors*, **2006**, 24, 197-208	1.6	36
19	PAX3-FKHR chimeric oncoprotein: hiding itself from immune detection?. *Cell Cycle*, **2006**, 5, 563-4	4.7	1
18	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. *Pediatric Blood and Cancer*, **2006**, 46, 820-4	3	7
17	A molecular map of mesenchymal tumors. *Genome Biology*, **2005**, 6, R76	18.3	104

16	Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. *Blood*, **2005**, 105, 2510-8	2.2	146
15	Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. *Journal of Experimental Medicine*, **2005**, 202, 1399-410	16.6	48
14	Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. *Journal of Clinical Oncology*, **2005**, 23, 880-8	2.2	95
13	The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. *Journal of Biological Chemistry*, **2004**, 279, 21617-27	5.4	32
12	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. *Cancer Genetics and Cytogenetics*, **2003**, 140, 73-7		30
11	Response without shrinkage in bilateral Wilms tumor: significance of rhabdomyomatous histology. *Journal of Pediatric Hematology/Oncology*, **2002**, 24, 31-4	1.2	38
10	Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. *Medical and Pediatric Oncology*, **2001**, 36, 259-67		62
9	PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. *American Journal of Pathology*, **2001**, 159, 1089-96	5.8	61
8	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study **2001**, 36, 259		3
7	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma **2000**, 28, 220-226		62
6	Genes, chromosomes, and rhabdomyosarcoma. *Genes Chromosomes and Cancer*, **1999**, 26, 275-285	5	129
5	Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. *Neoplasia*, **1999**, 1, 340-8	6.4	67
4	Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. *Genes Chromosomes and Cancer*, **1996**, 17, 7-13	5	41
3	Osteogenesis imperfecta is linked to both type I collagen structural genes. *Lancet, The*, **1986**, 2, 69-72	40	144
2	Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors. *Exploration of Immunology*,168-179		0
1	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. *F1000Research*,10, 947	3.6	